Joint Pain
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Leo PharmaLEO 158968
BioibericaNative type II collagen
BioibericaNative type II collagen
Clinical Trials (3)
Total enrollment: 161 patients across 3 trials
A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968
Start: Dec 2024Est. completion: Sep 20256 patients
Phase 1Completed
Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.
Start: Apr 2026Est. completion: Mar 202780 patients
N/ANot Yet Recruiting
NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort
Start: Mar 2022Est. completion: Mar 202475 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.